If proven effective, GLP-1 RAs could represent a novel and impactful treatment strategy for delaying or preventing kidney failure in patients with AS and other causes of CKD, thereby significantly improving their long-term prognosis and quality of life. This evidence concerns the gene GLP1R and chronic kidney disease.